AnteoTech (ASX:ADO) share price lifts as Ellume US sales ramp-up

Anteotech shares are sharing in the love as unlisted Ellume ramps up for a COVID-19 sales boom…

| More on:
two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AnteoTech Ltd (ASX: ADO) share price is bouncing around today with above-average trading volume. This comes as Ellume secures further approvals from the United States Food and Drug Administration (FDA) for its COVID-19 rapid antigen home test.

At the time of writing, the AnteoTech share price is up 4.17% to 25 cents. Meanwhile, the trading volume is around 4.3 million shares. This represents around 91% of the company's average volume for a whole month.

Let's look at the latest news and why AnteoTech shares are returning a positive reading today.

More tests to fly out the door

For those unaware, AnteoTech is connected to Ellume by providing its 'AnteoBind' technology for Ellume's at-home tests.

According to recent reports, Brisbane-based Ellume is ramping up its rollout of the tests across the United States. This follows the local company receiving approval from the FDA to sell COVID tests to point-of-care providers. Such providers include doctors, pharmacists, and commercial venues.

While millions of at-home COVID tests are flying off the shelves, Australia can't say the same. Due to Australian legislation, over-the-counter test kits are currently banned locally.

Additionally, in an interview with The Australian Financial Review, Ellume founder and CEO Mr Sean Parsons said:

Right now, the TGA [Therapeutic Goods Administration] are not able to review a submission we make for a home COVID test because there is a piece of legislation that is prohibiting them. Their hands are tied. The law was written when pandemics weren't really imagined and they wanted to force people to record how many of those illnesses [went] through the health system. I don't think it really makes sense now

The statement is timely given the current situation faced by the New South Wales Government. A further 98 local COVID-19 cases were recorded by the state overnight.

ASX-listed AnteoTech rides the Ellume buzz

The Anteotech share price has had a cracking 12 months, with shares gaining around 650% over the period. Incidentally, AnteoTech is possibly benefitting from the fact that Ellume is not a publically listed company. With Ellume being an AnteoTech customer, investors might consider the ASX-listed company to be the next best thing.

Finally, the AnteoTech share price was the best performing ASX-listed healthcare share in FY21. The company now holds a market capitalisation of around $478.5 million.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »